Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic...

Area of Science:

• Ophthalmology
• Genetics
• Pharmacogenomics

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss.
• Intraocular anti-vascular endothelial growth factor (VEGF) therapies are standard treatment for DME.
• Individual responses to anti-VEGF therapy for DME vary significantly.

Purpose of the Study:

• To identify genetic determinants associated with anti-VEGF treatment response in patients with DME.
• To explore genetic loci that predict changes in central macular thickness (CMT) and best-corrected visual acuity (BCVA) after anti-VEGF therapy.

Main Methods:

• Genome-wide association study (GWAS) conducted on 220 Australian DME patients treated with anti-VEGF therapy.
• Genotyping performed using Illumina Global Screening Array, imputed to Haplotype Reference Consortium panel.
• Association analysis using linear regression, adjusting for relevant clinical and demographic factors.

Main Results:

• Two loci on chromosomes 6 and 12 showed genome-wide significance for association with increased CMT.
• Four loci on chromosomes 5 and 11 were significantly associated with reduction in BCVA.
• In silico analysis identified potential candidate genes and expression quantitative trait loci at these significant loci.

Conclusions:

• Multiple genetic loci predict treatment outcomes for anti-VEGF therapies in DME.
• These findings support the potential for personalized treatment strategies in managing DME based on genetic profiles.
• Further research into identified loci and candidate genes is warranted to refine personalized medicine approaches for DME.